Related Experiment Videos
Current pharmacotherapy for acromegaly: a review
Nienke R Biermasz1, Johannes A Romijn, Alberto M Pereira
1Department of Endocrinology and Metabolism, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. nrbiermasz@lumc.nl
Expert Opinion on Pharmacotherapy
|November 2, 2005
Summary
Effective treatment for acromegaly, including surgery and pharmacotherapy, significantly reduces associated risks. A new algorithm individualizes treatment based on patient and disease factors, balancing lifelong medication costs against surgical outcomes.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Acromegaly, caused by excess growth hormone, leads to significant morbidity and mortality.
- While surgery and pharmacotherapy are established treatments, advances have refined their application.
- Radiotherapy's role is now limited due to newer therapeutic options like pegvisomant.
Purpose of the Study:
- To review current treatment options for acromegaly, including surgery, radiotherapy, and pharmacotherapy.
- To discuss pharmacological characteristics, clinical effects, and adverse events of available medications.
- To propose an individualized treatment algorithm balancing medical and surgical interventions.
Main Methods:
- Comprehensive review of acromegaly treatment modalities: surgery, radiotherapy, and pharmacotherapy.
- Analysis of pharmacotherapy including somatostatin analogues (octreotide, lanreotide), pegvisomant, and cabergoline.
- Discussion of treatment goals, costs, and a proposed individualized treatment algorithm.
Main Results:
- Effective acromegaly treatment improves both morbidity and mortality risks.
- Pharmacotherapy alone or combined with surgery controls growth hormone excess in most patients.
- A new algorithm individualizes primary treatment choice based on adenoma characteristics and patient factors.
Conclusions:
- Treatment choice for acromegaly should be individualized, considering adenoma specifics, patient factors, and center expertise.
- Pharmacological treatments offer effective control but involve high lifelong costs, particularly pegvisomant.
- The cost-effectiveness of lifelong medical treatment must be compared to that of a single surgical procedure.